title: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.
abstract: Osteopontin (OPN) has been implicated as an important mediator of breast cancer progression and metastasis and has been investigated for use as a potential therapeutic target in the treatment of breast cancer. However, the in vivo antitumor effect of anti-OPN antibodies on breast cancer has not been reported. In this study, a mouse anti-human OPN antibody (1A12) was humanized by complementarity-determining region grafting method based on computer-assisted molecular modeling. A humanized version of 1A12, denoted as hu1A12, was shown to possess affinity comparable to that of its parental antibody. The ability of hu1A12 to inhibit cell migration, adhesion, invasion and colony formation was assessed in a highly metastatic human breast cancer cell line MDA-MB-435S. The results indicated that hu1A12 was effective in inhibiting the cell adhesion, migration, invasion and colony formation of MDA-MB-435S cells in vitro. hu1A12 also showed significant efficacy in suppressing primary tumor growth and spontaneous metastasis in a mouse lung metastasis model of human breast cancer. The specific epitope recognized by hu1A12 was identified to be (212)NAPSD(216), adjacent to the calcium binding domain of OPN. Our data strongly support that OPN is a potential target for the antibody-based therapies of breast cancer. The humanized anti-OPN antibody hu1A12 may be a promising therapeutic agent for the treatment of human breast cancer.
authors.affiliation: International Joint Cancer Institute and General Hospital Cancer Center, The Second Military Medical University, Shanghai, People's Republic of China.
authors.forename: Jianxin
authors.initials: J
authors.lastname: Dai
authors.forename: Bohua
authors.initials: B
authors.lastname: Li
authors.forename: Jinping
authors.initials: J
authors.lastname: Shi
authors.forename: Ling
authors.initials: L
authors.lastname: Peng
authors.forename: Dapeng
authors.initials: D
authors.lastname: Zhang
authors.forename: Weizhu
authors.initials: W
authors.lastname: Qian
authors.forename: Sheng
authors.initials: S
authors.lastname: Hou
authors.forename: Lei
authors.initials: L
authors.lastname: Zhao
authors.forename: Jie
authors.initials: J
authors.lastname: Gao
authors.forename: Zhiguo
authors.initials: Z
authors.lastname: Cao
authors.forename: Jian
authors.initials: J
authors.lastname: Zhao
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.forename: Yajun
authors.initials: Y
authors.lastname: Guo
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000196:embryology / Q000473:pathology; D018604:Epitope Mapping; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D053495:Osteopontin / Q000235:genetics / Q000276:immunology*; D011995:Recombination, Genetic; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D053495:Osteopontin
references.citation: J Biol Chem. 1994 Sep 16;269(37):23280-5
references.pmid: 8083234
references.citation: J Biol Chem. 2003 Aug 1;278(31):28593-606
references.pmid: 12771144
references.citation: Anticancer Res. 1989 Sep-Oct;9(5):1291-9
references.pmid: 2686530
references.citation: Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90
references.pmid: 14734468
references.citation: Lancet. 2001 Jul 28;358(9278):277-86
references.pmid: 11498214
references.citation: Int Immunopharmacol. 2007 Nov;7(11):1460-70
references.pmid: 17761350
references.citation: J Cell Mol Med. 2008 Dec;12(6A):2305-18
references.pmid: 18266970
references.citation: Int J Cancer. 1998 Oct 23;79(5):502-8
references.pmid: 9761120
references.citation: Am J Pathol. 1994 Sep;145(3):610-23
references.pmid: 8080043
references.citation: Proc Natl Acad Sci U S A. 1989 Dec;86(24):10029-33
references.pmid: 2513570
references.citation: J Biol Chem. 2003 Apr 18;278(16):14487-97
references.pmid: 12473670
references.citation: Int J Oncol. 2004 May;24(5):1235-44
references.pmid: 15067347
references.citation: Cancer Res. 2002 Jun 15;62(12):3417-27
references.pmid: 12067984
references.citation: Int J Exp Pathol. 2000 Dec;81(6):373-90
references.pmid: 11298186
references.citation: Nat Med. 2003 Apr;9(4):416-23
references.pmid: 12640447
references.citation: Lung Cancer. 2007 Sep;57(3):302-10
references.pmid: 17482311
references.citation: Am J Pathol. 2007 Aug;171(2):682-92
references.pmid: 17620367
references.citation: Am J Pathol. 2006 Jul;169(1):233-46
references.pmid: 16816376
references.citation: Clin Cancer Res. 1997 Apr;3(4):605-11
references.pmid: 9815727
references.citation: Ann N Y Acad Sci. 1995 Apr 21;760:299-301
references.pmid: 7785904
references.citation: J Immunol Methods. 1994 Feb 10;168(2):149-65
references.pmid: 8308291
references.citation: Protein Eng. 1991 Oct;4(7):773-83
references.pmid: 1798701
references.citation: Oncogene. 1999 Jul 22;18(29):4237-46
references.pmid: 10435636
references.citation: Lancet. 2005 Dec 17;366(9503):2087-106
references.pmid: 16360786
references.citation: Biochem J. 1994 Oct 1;303 ( Pt 1):255-62
references.pmid: 7945249
references.citation: J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29
references.pmid: 12013531
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1087-97
references.pmid: 17548669
references.citation: Immunology. 2005 Dec;116(4):487-98
references.pmid: 16313362
references.citation: Cancer Res. 1994 Feb 1;54(3):832-7
references.pmid: 8306346
references.citation: Carcinogenesis. 2005 Apr;26(4):741-51
references.pmid: 15661802
references.citation: J Surg Res. 2004 Oct;121(2):228-41
references.pmid: 15501463
references.citation: J Neurosci. 2007 Mar 28;27(13):3603-11
references.pmid: 17392476
references.citation: FASEB J. 1993 Dec;7(15):1475-82
references.pmid: 8262332
references.citation: Biol Trace Elem Res. 2006 Jan;109(1):55-60
references.pmid: 16388103
references.citation: Crit Rev Oncog. 1996;7(3-4):261-91
references.pmid: 9258606
references.citation: Immunol Today. 1993 Jun;14(6):243-6
references.pmid: 8397764
references.citation: Nature. 1984 Dec 13-19;312(5995):643-6
references.pmid: 6095115
references.citation: Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5
references.pmid: 6436822
references.citation: Arthritis Rheum. 2008 Jul;58(7):2041-52
references.pmid: 18576331
references.citation: Nat Rev Cancer. 2002 Aug;2(8):563-72
references.pmid: 12154349
references.citation: Curr Mol Med. 2001 Nov;1(5):621-32
references.pmid: 11899236
references.citation: Clin Exp Metastasis. 2006;23(2):123-33
references.pmid: 16830223
references.citation: Trends Cell Biol. 2006 Feb;16(2):79-87
references.pmid: 16406521
references.citation: J Immunol. 1996 Apr 15;156(8):2840-50
references.pmid: 8609403
references.citation: Biochim Biophys Acta. 1996 Nov 8;1314(1-2):13-24
references.pmid: 8972713
references.citation: Nature. 1986 May 29-Jun 4;321(6069):522-5
references.pmid: 3713831
references.citation: Cancer Res. 1985 Feb;45(2):879-85
references.pmid: 3871353
references.citation: J Immunol. 1993 Sep 1;151(5):2623-32
references.pmid: 8360482
references.citation: J Cell Biochem. 1994 Feb;54(2):247-55
references.pmid: 8175899
references.citation: Mol Biotechnol. 2004 Jan;26(1):39-60
references.pmid: 14734823